The unique water-free investigational drug increases residual time on the ocular surface and enables a high bioavailability in the target tissues to unfold the full potential of cyclosporine A and fast onset of action within 2 weeks.
The multi-dose, preservative-free, smaller and more physiologic drop size profile provides unique clinical benefits and outstanding tolerability.
An early onset of action, clinically significant efficacy on signs and symptoms and excellent comfort, as shown in the ESSENCE Phase 3 program, differentiates CyclASol® from existing therapies.
Results from the long-term extension study ESSENCE-2 OLE confirmed that the effect of CyclASol® was maintained, and even improved for most endpoints, over the 52-week treatment period.
Today anti-inflammatory therapeutic options are standard for care in DED. Inflammation is the key underlying driver of the disease as chronic immunologic processes have a pivotal role in the pathology of dry eye. The chronic inflammatory nature of DED also causes progressive corneal surface damage. Corneal surface damage can negatively affect visual function and any refractory eye care outcome in particular in cataract or refractive patients where dry eye is common.
Despite several anti-inflammatory therapeutic options approved, there is a large unmet need for a therapy that can rapidly and reliably repair corneal surface damage secondary to DED. Also better comfort is a high unmet need.
